Lawsuit alleges Hormel Foods denied workers earned safe and sick time
The class action lawsuit alleges Hormel violated the Minnesota Earned Safe and Sick Time law for UFCW Local 663 members. The union represents more than 1,600 meatpacking workers at Hormel's Austin, Minnesota, plant.
The lawsuit claims workers had to use vacation days instead of sick days if they wanted to get paid for the time off. Hormel is accused of refusing to provide employees with earned sick and safe time (ESST) benefit accruals for their work between Jan. 1, 2024, and March 1, 2025, and denying the workers' statutory right to carry over their accrued, unused ESST benefits into the 2025 calendar year. The lawsuit also alleges Hormel failed to give "all or most" employees any of the ESST benefits they earned in January and February this year,
"Workers, advocates, and legislators fought hard to make Earned Sick and Safe Time law. Now, ESST is a statewide standard," said UFCW Local 663 President Rena Wong. "UFCW 663 members know what it means to fight for what we deserve and win. After all, workers at Hormel set the standard for wages in the meatpacking industry."
Hormel declined to comment.
The lawsuit is the first of its kind since the law passed in 2023, according to the Minnesota Senate DFL. Under the law, anyone is eligible for the sick and safe time if they work 80 hours a year and don't qualify as an independent contractor.
The policy approved by the DFL-led legislature allows people to use the time for treating mental or physical illness, going to medical appointments, caring for a family member who's ill, and even due to inclement weather that may close children's school and keep them home. It also covers absences related to domestic abuse or sexual assault.
"As chief author of the 2023 Earned Sick and Safe Time law, I am proud to stand with the workers of UFCW Local 663 as they demand the rights they are due," Sen. Sandra Pappas, DFL-St. Paul, said. "Hormel must follow Minnesota law and stop disrespecting its workers. I look forward to UFCW Local 663's day in court."
There's a long history of labor activism at the Hormel plant in Austin. In the mid-1980s, about 1,500 workers went on strike for 13 months in one of the longest strikes in state history. The employees cited a wage freeze, dangerous working conditions and a wage cut as the reason for the strike.Caroline Cummings
contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Brachytherapy Devices Market is Growing at CAGR of 6.7% During 2025 -2031 to Reach US$534.20 Million
NEW YORK, Aug 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the Brachytherapy Devices Market is witnessing significant growth due to the rising incidence of cancer worldwide and technological advancements in brachytherapy devices. The Brachytherapy Devices Market value is expected to reach US$534.20 million by 2031 from US$343.57 million in 2024; the market is anticipated to register a CAGR of 6.7% during 2025–2031. The market growth is attributed to the rising incidence of cancer worldwide, the aging population, and the technological advancements in brachytherapy devices. The Brachytherapy Devices Market analysis focuses on advancements such as MRI-compatible applicators and real-time imaging integration that play a vital role in the market growth. The report runs an in-depth analysis of market trends, key players, and future opportunities. Check valuable insights in the Brachytherapy Devices Market report. You can easily get a sample PDF of the report - Overview of Brachytherapy Devices Market Report Findings Rising Incidence of Cancer Worldwide:As per the GLOBOCAN 2020 report, more than 28.4 million new cancer cases are expected to be reported by 2040. An aging population, lack of physical activity, exposure to pollutants in the environment, and alterations in diet lead to increased rates of an internal radiation treatment, is ideal for the treatment of prostate, cervical, breast, and skin cancers. It allows for the radiation to be targeted directly to the tumor and avoid the surrounding healthy tissues, with reduced side effects and improved recovery times. Thus, brachytherapy is becoming increasingly popular among oncologists and cancer remains among the major causes of mortality globally, demand for effective, low-invasive, and affordable treatment procedures is rising. Brachytherapy is meeting this demand, particularly in facilities where it might not be possible to access highly advanced external radiation facilities. Thus, the increasing burden of cancers worldwide propels the market growth. Technological Advancements in Brachytherapy Devices:Advances in the area are improving the accuracy, safety, and effectiveness of treatments, making brachytherapy a progressively appealing choice for cancer technological advancements include the creation of high-dose rate (HDR) and low-dose rate (LDR) machines, which provide more accurate radiation delivery. HDR machines provide for administering higher doses of radiation in shorter times, making treatment faster and more convenient for patients. MRI-compatible applicators and integration of sophisticated imaging are providing better tumor localization and online monitoring of treatment. These advances allow clinicians to target tumors effectively with less exposure to healthy tissues in the proximity. The robot-assisted platforms provide higher accuracy and precision, particularly in challenging anatomical areas. In addition, miniaturization and mobility of brachytherapy equipment are facilitating treatments, especially in developing advances in technology are making brachytherapy more effective and safer but and increasing its uses in treating a broader spectrum of cancers. Consequently, the greater uptake of these machines is contributing to their adoption and setting the limits of cancer treatment even higher. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and Asia Pacific. Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on Brachytherapy Devices Market Trends: Brachytherapy Devices Market Segmentation Based on product, the Brachytherapy Devices Market is segmented into seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy. The brachytherapy afterloaders segment held the largest market share in 2024. In terms of type, the Brachytherapy Devices Market is categorized into high-dose rate brachytherapy implant and low-dose rate brachytherapy implant. The low-dose rate brachytherapy implant segment dominated the market in 2024. By application, the Brachytherapy Devices Market is segmented into breast cancer, cervical cancer, prostate cancer, lung cancer, and others. The prostate cancer segment dominated the market in 2024. Per end user, the Brachytherapy Devices Market is divided into hospitals and specialty clinics, ambulatory surgical centers, and others. The hospitals and specialty clinics segment dominated the market in 2024. The Brachytherapy Devices Market is segmented into five major regions: North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. Competitive Strategy and Development Key players: Elekta, Varian Medical Systems, Inc., BEBIG Medical, Theragenics Corporation, IsoAid, Siemens Healthineers AG, BXTA, BD, and Eckert and Ziegler are among the major companies operating in the Brachytherapy Devices Market. Trending topics: Advancements in Imaging Technologies, Government Initiatives and Cancer Treatment Programs, Technological Advancements in Brachytherapy Devices, Integration of Artificial Intelligence (AI) and Robotics in brachytherapy, etc. Headlines on Brachytherapy Devices Market Artemis Hospital Announces the Launch of Brachytherapy Services, Expanding Advanced Cancer Care Papua New Guinea Resumes Radiotherapy, Starts Brachytherapy Services with IAEA Support BEBIG Medical Launches SagiNova Brachytherapy System at Father Muller Hospital as a Part of New Healthcare Wing Medanta Patents MAOLO Brachytherapy Device For Advanced Cervical Cancer Treatment Elekta Expands Brachytherapy Portfolio With Acquisition of iCad Inc.'s Xoft Business CivaTech Oncology Receives FDA Approval for CivaSheet Brachytherapy Device Get Premium Copy of Brachytherapy Devices Market Size and Growth Report by 2031 at: Conclusion The growth of the Brachytherapy Devices Market is fueled by the increasing prevalence of cancer, advances in technology, and soaring demand for minimally invasive treatment options. The high-dose rate (HDR) systems, MRI-compatible applicators, and robotic-assisted devices are increasing the accuracy of treatment and speeding up patient recovery. Further, there is a growing demand for affordable and patient-centric therapies, particularly in areas that have poor access to conventional cancer therapy. With increasing uses in prostate, breast, and cervical cancers, the demand for brachytherapy is surging, with better results and accessibility in cancer therapy. The report from The Insight Partners provides several stakeholders—including manufacturers of seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy devices—with valuable insights to navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: Brachytherapy After Loaders Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031 Cancer Therapy Market Scope, Share, and Size by 2031 Pancreatic Cancer Therapy Market SWOT Analysis by 2031 Lung Cancer Therapy Market Research Report by 2030 Cancer Biopsies Market Trends, Share, and Growth – 2031 Cervical Cancer Diagnostics and Therapeutics Market Size 2031 Kidney Cancer Therapeutics And Diagnostics Market Size 2031 Cancer Biopsies Market Trends, Share, and Growth - 2031 Thyroid Cancer Diagnostics Market Growth and Share by 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact Us:If you have any queries about this report or if you would like further information, please get in touch with us:Contact Person: Ankit MathurE-mail: +1-646-491-9876 Logo: View original content: SOURCE The Insight Partners Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 minutes ago
- Yahoo
RETIRED PHYSICIAN AND FORMER STATE LEGISLATOR JANAK JOSHI ANNOUNCES CAMPAIGN FOR U.S. SENATE
DENVER, Aug. 4, 2025 /PRNewswire/ -- Retired Colorado Springs Physician and former state legislator Dr. Janak Joshi has announced his candidacy for the United States Senate, mounting an aggressive challenge against career politician John Hickenlooper. "I arrived in America legally and with nothing but a suitcase and $100. Through hard work and deep appreciation for our Country, I found the American dream. Career politicians like John Hickenlooper are on a warpath to destroy the very fabric that makes America that land of opportunity. In the state legislature, I fought toe-to-toe against his radical ideals and drew a line in the sand between him and the constituents that sent me to Denver. I was a thorn in Hickenlooper's side - I never voted for a tax, fee, or spending increase. I never voted for his wasteful pet projects thrown onto the shoulders of the Colorado taxpayer. It's time to send Hickenlooper packing - and I'm the candidate to get the job done. This country gave me and my family the opportunity to find the American dream. Hickenlooper and radical progressives in D.C. are trying to destroy it. I have led a life of commitment to serve others, uphold the rule of law, and defend Colorado's values. That's exactly what I'll do in the United States Senate." Dr. Janak Joshi arrived in America legally, with a suitcase and $100. He went on to serve as a Colorado Springs physician for 30 years and served in the Colorado state legislature. Joshi has a proven track record of creating good-paying jobs, standing up for law and order, defending conservative values, and fighting back against the woke liberal agenda. Learn more: View original content to download multimedia: SOURCE Janak Joshi for U.S. Senate
Yahoo
4 minutes ago
- Yahoo
Millions of women get UTIs each year. An antibiotic 30 years in the making is finally offering hope.
The new medication performs just as well as the current top treatment for UTIs. Most UTIs, or urinary tract infections, are anything but subtle. When you've got one, you constantly feel like you need to pee even if you just went, it burns when you go and your urine looks suspiciously cloudy. UTIs are also quite common: More than 50% of women will deal with at least one in their lifetime, and what's worse is that these infections can come back in a matter of months. Treating them has also become trickier. That's because there's a growing number of antibiotic-resistant UTIs, meaning the drugs commonly used to kill the bacteria behind the infection no longer work as well. 'Not only are these infections painful and unpleasant, they are becoming more difficult to treat,' says Dr. Cynthia DeTata, an ob-gyn at Stanford Medicine Children's Health and a clinical assistant professor in maternal-fetal medicine at Stanford Medicine, tells Yahoo. She explains that the most common cause of antibiotic resistance is taking the medications improperly, such as not finishing the entire course of pills as prescribed. 'Partially treating an infection allows rebound growth of bacteria that are now resistant to that antibiotic,' she explains. Experts say there's an increasing need for new treatments to get UTIs back under control. The challenge? 'The last time a new antibiotic was approved for an uncomplicated UTI was 30 years ago. Our treatments have remained unchanged, while bacteria have continued to evolve,' Dr. Gil Weiss, an ob-gyn at the Association for Women's Health Care and assistant professor of clinical medicine in the department of obstetrics and gynecology at Northwestern Memorial Hospital in Chicago, tells Yahoo. Now for some good news: There's a new antibiotic on the market called gepotidacin (sold under the brand name Blujepa) that gives doctors a new way to fight pesky UTIs. It's the first new class of antibiotics since the 1990s, and experts say it can help treat UTIs with a lower risk of resistance. The problem: While there are effective drugs for UTIs, antibiotic-resistant infections are making them harder to treat. By the numbers: UTIs affect up to 16 million women in the U.S. annually, and for 30 to 44% of them, the infection will come back in a matter of months. Studies suggest that 92% of bacteria behind UTIs are resistant to at least one antibiotic, and nearly 80% don't respond to at least two antibiotics. The solution: In March 2025, the Food and Drug Administration approved gepotidacin to treat uncomplicated UTIs. (Drugs Pivya and Orlynvah were approved in 2024 to treat UTIs, but they fall into existing antibiotic classes.) 'Gepotidacin is part of a new class of antibiotics called triazaacenaphthylenes,' DeTata says. 'This class is so new that currently, gepotidacin is the only one in it.' Antibiotics fight bacteria in two main ways: They can kill bacteria (bactericidal) or they can prevent them from multiplying (bacteriostatic), says DeTata. For example, some antibiotics interfere with the formation of bacteria cell walls, causing the wall to burst and killing the bacteria, while others disrupt the synthesis of proteins, which bacteria need to survive. 'Gepotidacin works in an entirely new way by acting on enzymes called topoisomerases, leading to breaks in the DNA strands of bacteria,' DeTata says. 'So gepotidacin is bactericidal, as these breaks in the DNA strands kill the bacteria.' The drug's main side effects in clinical trials were diarrhea (16% of participants) and nausea (9%), both which are common side effects for antibiotics in general. The research also found that gepotidacin performs just as well as (if not better than) nitrofurantoin, which is a frontline treatment for UTIs. Added bonus: Gepotidacin 'has the potential to be used for the treatment of gonorrhea, which has also been difficult to treat due to multi-antibiotic resistance,' says DeTata. For Weiss and many other doctors, having a new treatment option for UTIs is something to celebrate. 'I'm very excited that a new medication has come to market,' he says. 'Any new medication for something so common is a win-win situation.' Solve the daily Crossword
